Nexgenia

Seattle, United States Founded: 2011 • Age: 15 yrs
Develops and manufactures proprietary polymers and polymer-containing magnetic nanoparticles for diagnostics and life science applications.

About Nexgenia

Nexgenia is a Healthcare company based in Seattle (United States) founded in 2011. It develops and manufactures proprietary polymers and polymer-containing magnetic nanoparticles for diagnostics and life science applications. It operates in the Healthcare, Technology, and Chemicals & Materials sectors. Nexgenia has raised $3.98 million across 5 funding rounds from investors including The W Fund and Gamespools. The company has 2 employees. Nexgenia offers products and services including Smart Magnetic Nanoparticles. Its focus areas include High Tech, Advanced Materials, Nanostructures and Metal and Metalloid. Its legal entity is NEXGENIA INC. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.

Company details

Nexgenia develops and manufactures reagent systems that combine stimuli-responsive polymers with magnetic nanoparticles to enable rapid recognition of target molecules. The company develops and validates stimuli-responsive nanoparticles with the ability to co-aggregate for cell separation for use in cancer immunotherapies and other medical applications. It offers specialty chemicals and materials for manufacturers of in vitro diagnostic assays, and for life science applications related to assays and molecular separations; and distributors of products for diagnostic testing.

  • Headquarters Seattle, United States
  • Employees 2
  • Sectors
    Healthcare
    Technology Chemicals & Materials
  • Website nexgeniacorp.com
  • Social X
  • Legal Name Nexgenia Inc
Key Metrics
  • Total Equity Funding
    $3.98M (USD)

    in 5 rounds

  • Latest Funding Round
    $119.1K (USD), Debt – Conventional

    May 2018

  • Investors
    The W Fund

    & 1 more

  • Employee Count
    2

Products & Services of Nexgenia

Nexgenia offers a comprehensive portfolio of products and services, including Smart Magnetic Nanoparticles.

Smart Magnetic Nanoparticles
Diagnostic Reagents

Improve speed and sensitivity for molecular and cell separations in testing

Funding Insights of Nexgenia

Nexgenia has successfully raised a total of $3.98M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $119.1 thousand completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $3.98M
  • Total Rounds 5
  • Last Round Debt – Conventional β€” $119,099
  • First Round $249,900

    (Aug 2014)

  • Investors Count 2

All 5 funding rounds of Nexgenia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2018$119,099Debt – Conventional––
–
Aug 2016$1.86MSeries A––
–
Jun 2015$1.62MSeries A––
–
Oct 2014$500,000Seed––
Aug 2014$249,900Grant––
Valuation history

2 investors in total: 2 institutional.

Investors in Nexgenia

Nexgenia has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include The W Fund and Gamespools.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
thewfund.com
Gamespools is recognized as an online slot gaming platform.
lsdfa.orgIndonesia
Premium access

Investor details for Nexgenia

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Nexgenia

1 people are tracked at Nexgenia (1 in leadership); the tracked headcount is 2.

NameRoleGroup
Ron Myers
CEOLeadership
Premium access

Complete people profiles for Nexgenia

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Nexgenia

3 dated milestones of Nexgenia across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded Nexgenia is founded.
  2. Funding First funding round of $250K.
  3. Funding Latest funding round, Debt – Conventional, of $119K.

Competitors of Nexgenia

Nexgenia has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
aviditybiosciences.com2012San Diego, United States$142.54M253
Antibody-siRNA complexes are developed for cancer treatment.
sutrobio.com2003United States$171.85M235
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
vividion.com2016Oceanside, United States$270.5M123
Developing novel drugs based on a proteome-wide ligand and target discovery platform
Premium access

Detailed competitors of Nexgenia

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Nexgenia (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Nexgenia

Nexgenia was founded in 2011 and raised its 1st funding round 3 years after it was founded.

Nexgenia is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.

Nexgenia is a funded company, having raised a total of $3.98M across 5 funding rounds to date. The company's 1st funding round was a Grant of $249.9K, raised on Aug 2014.

Nexgenia has 2 employees.

Nexgenia develops and manufactures reagent systems that combine stimuli-responsive polymers with magnetic nanoparticles to enable rapid recognition of target molecules. The company develops and validates stimuli-responsive nanoparticles with the ability to co-aggregate for cell separation for use in cancer immunotherapies and other medical applications. It offers specialty chemicals and materials for manufacturers of in vitro diagnostic assays, and for life science applications related to assays and molecular separations; and distributors of products for diagnostic testing.

Nexgenia's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.

Nexgenia offers Smart Magnetic Nanoparticles.

Nexgenia has 2 investors. Key investors include The W Fund, and Gamespools.

Nexgenia operates through Nexgenia Inc.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available